PurposeWe aimed to describe the demographics,
cancer MESHD subtypes, comorbidities and outcomes of patients with a history of
cancer MESHD with
COVID-19 MESHD from March to June 2020. Secondly, we compared patients hospitalized with
COVID-19 MESHD to patients diagnosed with
COVID-19 MESHD and patients hospitalized with influenza.
MethodsWe conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of
cancer MESHD were included: i) diagnosed with
COVID-19 MESHD, ii) hospitalized with
COVID-19 MESHD, and iii) hospitalized with influenza in 2017-2018. Patients were followed from index date to 30 days or
death MESHD. We reported demographics,
cancer MESHD subtypes, comorbidities, and 30-day outcomes.
ResultsWe included 118,155 patients with a
cancer MESHD history in the
COVID-19 MESHD diagnosed and 41,939 in the
COVID-19 MESHD hospitalized cohorts. The most frequent
cancer MESHD subtypes were prostate and
breast cancer MESHD (range: 5-19% and 1-14% in the diagnosed cohort, respectively).
Hematological malignancies MESHD were also frequent, with
non-Hodgkins lymphoma MESHD being among the 5 most common
cancer MESHD subtypes in the diagnosed cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the diagnosed and hospitalized
COVID-19 MESHD cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of
cancer MESHD subtypes, sex, age and comorbidities but lower occurrence of adverse events.
ConclusionPatients with a history of
cancer MESHD and
COVID-19 MESHD have advanced age, multiple comorbidities, and a high occurence of
COVID-19 MESHD-related events. Additionaly,
hematological malignancies MESHD were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.